Form 4: Supernus Director Converts RSUs to Common Stock

Supernus Pharmaceuticals Director Frederick M. Hudson converted 4,475 restricted stock units into common stock, increasing his direct beneficial ownership.

Summary

• Frederick M. Hudson, a Director of Supernus Pharmaceuticals, Inc. (SUPN), reported a change in beneficial ownership.
• On February 24, 2026, Hudson acquired 4,475 shares of Supernus common stock.
• Concurrently, 4,475 restricted stock units (RSUs) were disposed of, as they vested and were settled into common stock.
• The transaction price for both the acquisition of common stock and the disposal of RSUs was $0.
• Following these transactions, Hudson directly beneficially owns 65,782 shares of Supernus common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine compensation vesting and increases the director's direct equity stake, aligning interests.

Positives

• Director Frederick M. Hudson's direct beneficial ownership of Supernus common stock increased to 65,782 shares following the vesting and settlement of restricted stock units, aligning his interests further with shareholders.

Industry Context

StockSavvy.ai notes that routine insider transactions like RSU vesting and conversion to common stock are common and generally reflect compensation plans rather than discretionary market purchases or sales, indicating a standard operational event within the pharmaceutical industry.

Comparison to Industry Standards

• The vesting and settlement of restricted stock units into common stock is a standard compensation practice for directors and executives across various industries, including pharmaceuticals, aligning their interests with shareholders.

Stakeholder Impact

• Shareholders: Increased alignment of Director Frederick M. Hudson's interests with shareholders due to higher direct equity ownership.

Key Dates

Recommendation

This Form 4 reports a routine vesting of restricted stock units into common stock for a director. It does not indicate any discretionary buying or selling activity that would suggest a change in the company's fundamental outlook or warrant a strong buy/sell recommendation. It's a neutral event for investment decisions.

Keywords

Supernus Pharmaceuticals, SUPN, insider transaction, stock ownership, director, restricted stock units, RSU vesting